CTLA4 and cancer: The anti-CTLA4 mAb, ipilimumab, the first immune checkpoint inhibitor for immunotherapy of cancer patients, blocks negative signals on effector T cells [71], but can also deplete Treg cells or block Treg suppression [69,70].